Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3143753 (Part A)
LY3143753 · 1 trial · 1 indication
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| Arm | Type | Description |
|---|---|---|
| LY3143753 (Part A) | EXPERIMENTAL | Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1 |
| LY3185643 (Part B) | EXPERIMENTAL | Single SC injection of ascending doses of LY3185643 on Day 1 |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single SC injection of normal saline on Day 1 |
| rGlucagon (Part B) | ACTIVE_COMPARATOR | Single SC injection on Day 1 |
| Placebo (Part B) | PLACEBO_COMPARATOR | Single SC injection of normal saline on Day 1 |
| Name | Type | Description |
|---|---|---|
| LY3143753 (Part A) | DRUG | Administered via SC injection |
| LY3185643 (Part B) | DRUG | Administered via SC injection |
| Placebo (Part A and Part B) | DRUG | Administered via SC injection |
| rGlucagon (Part B) | DRUG | Administered via SC injection |
Inclusion Criteria: * Overtly healthy males or females * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures Exclusion Criteria: * Are investigator site personnel directly affiliated with this study and their immediate fam...
LY3143753 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult participants in the United Kingdom. No therapeutic indication for LY3143753 has been disclosed, and the compound remains in early clinical development.
LY3143753 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound conducted in healthy volunteers in the United Kingdom.
LY3143753 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials of LY3143753 are currently listed. The compound is investigational and has not been approved by the FDA for any indication.
LY3143753 was evaluated in the Phase 1 trial NCT02342314, titled A Study of LY3143753 and LY3185643 in Healthy Participants. The trial enrolled 68 healthy volunteers in the United Kingdom, was randomized, double-blind, and placebo-controlled, and has been completed.
Yes. LY3143753 (Part A) is an alternative designation used for LY3143753, referring to a portion of the clinical program for the same compound. Both names refer to the investigational small molecule developed by Eli Lilly and Company.
No therapeutic indication has been disclosed for LY3143753. The compound has been tested only in healthy adult volunteers in a Phase 1 trial, not in patients with a specific disease. Its intended clinical use has not been publicly announced.